Skip to content

Cohort study of comorbidity between depression and behavioral addiction in adolescents

Cohort study of comorbidity between depression and behavioral addiction in adolescents

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093320
Enrollment
Unknown
Registered
2024-12-02
Start date
2023-05-05
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Sponsors

Hangzhou Seventh People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 19 Years

Inclusion criteria

Inclusion criteria: MDE inclusion criteria: a) Currently meets the diagnostic criteria for MDE in the Structured Clinical Interview (SCID-5RV, Investigator edition) of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM5) of the American Psychiatric Association; b) between the ages of 13 and 19; c) Culture: junior high school grade 2 or above; d) Race: Han; e) Right-handed; f) To participate in the study voluntarily and to have the informed consent signed by both myself and the legal guardian. Admission criteria of HC normal control group: a) Healthy adolescent volunteers matched with the MDE group in terms of sex, age, education, race and handedness; b) To participate in the study voluntarily and to have the informed consent signed by both myself and the legal guardian.

Exclusion criteria

Exclusion criteria: Exclusion criteria for MDE group: a) I or my legal guardian refuse to participate in the study or refuse to sign the informed consent; b) Patients with liver, kidney, heart, lung and other internal organ failure, malignant tumors, severe infections, active visceral bleeding, serious heart disease, non-alcoholic active hepatitis, AIDS, untreated syphilis, active tuberculosis, whole-body immune diseases, and other serious physical diseases, organic brain diseases, and neurological diseases deemed unsuitable for inclusion in this study; c) Those who meet DSM5 criteria for schizophrenia, bipolar disorder, schizoaffective disorder, organic mental disorder, substance-related mental disorder, or those diagnosed with mental retardation, autism spectrum disorder and other cognitive disorders; d) A proven history of head trauma; e) Unable to participate in follow-up evaluation; f) received electroconvulsive therapy); g) At the time of enrollment screening, there were still definite psychotic symptoms such as hallucinations and delusions, and the evaluating doctor judged that there was a high risk of suicide or the suicide entry of the Hamilton Depression Scale suggested a high risk of suicide; h) Patients with metal objects (such as metal dentures, pacemakers, etc.) affecting MRI examination; i) Color blindness. Exclusion criteria for normal control group: a) Those who have previously or currently met any of the disease diagnostic manifestations in DSM5; b) I or my legal guardian refuse to participate in the study or refuse to sign the informed consent; c) Patients with liver, kidney, heart, lung and other internal organ failure, malignant tumor, severe infection, active visceral bleeding, serious heart disease, non-alcoholic active hepatitis, AIDS, untreated syphilis, active tuberculosis, whole-body immune diseases, and other serious physical diseases, organic brain diseases, neurological diseases deemed unsuitable for inclusion in this study, or had taken medical treatment Use of antipsychotics, antidepressants, mood stabilizers; Use of benzodiazepines or other drugs affecting the central nervous system in the week prior to MRI examination; d) Family history: positive family history of mental illness in three generations of the second line; e) Subjects who need to work night shifts; f) A proven history of head trauma; g) Unable to participate in follow-up evaluation; h) Patients with metal objects (such as metal dentures, pacemakers, etc.) affecting MRI examination; i) Color blindness.

Design outcomes

Primary

MeasureTime frame
DSM-5;Child Behavior Checklist, CBCL;Hamilton Depression Scale, HAMD;Hamilton Anxiety Rating Scale, HAMA;Patient Health Questionnaire-9, PHQ-9;Generalized Anxiety Disorder-7, GAD-7;symptom checklist 90, SCL-9;Toronto Alexithymia Scale, TAS-20;Internet Gaming Disorder Scale-Short Form, IGD-9SF;The Young Internet Addiction Test;Bergen Social Media Addiction Scale, BSMAS;Non-Suicidal Self-Injury, NSSI;ASLEC/CTQ;

Secondary

MeasureTime frame
Multi-source multi-modal brain image structure and functional neuroimaging (high-resolution brain structure MRI, DTI, Rs-fMRI, task-state fMRI);High precision neural electrophysiology and other multi-time point multi-omics multi-modal data(EEG);

Countries

China

Contacts

Public ContactGuo Wanjun

Hangzhou Seventh People's Hospital

guowjcn@163.com+86 189 8060 2250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026